Recursion Pharmaceuticals (RXRX) Net Cash Flow (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Net Cash Flow data on file, last reported at -$84.9 million in Q1 2026.

• Quarterly Net Cash Flow rose 13.97% year-over-year to -$84.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.6 million (down 27.17% YoY) and the FY2025 annual result came in at $132.9 million, down 35.2% from the prior year.
• Net Cash Flow retreated to -$84.9 million in Q1 2026, from $84.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $222.8 million in Q1 2022 to a low of -$98.7 million in Q1 2025.
• A 5-year average of $21.1 million and a median of $780000.0 in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow plunged 2600.26% — and 2024, when it jumped 4068.66%.
• Tracing RXRX's Net Cash Flow over 5 years: stood at $94.5 million in 2022, then tumbled by 95.67% to $4.1 million in 2023, then jumped by 4068.66% to $170.7 million in 2024, then slumped by 50.38% to $84.7 million in 2025, then tumbled by 200.26% to -$84.9 million in 2026.
• The last three Net Cash Flow figures came in at -$84.9 million (Q1 2026), $84.7 million (Q4 2025), and $131.4 million (Q3 2025), per Business Quant data.